BYFAVO

This brand name is authorized in United States. It is also authorized in Croatia, Estonia, Finland, Ireland, Lithuania, Poland, Romania, UK.

Active ingredients

The drug BYFAVO contains one active pharmaceutical ingredient (API):

1	Remimazolam UNII 280XQ6482H - REMIMAZOLAM BESYLATE
	Remimazolam is an ultra-short acting benzodiazepine sedative. The effects of remimazolam on the CNS are dependent on the dose administered intravenously and presence or absence of other medicinal products. Remimazolam binds to benzodiazepine sites of gamma amino butyric acid type A [GABAA] receptors with high affinity, while its carboxylic acid metabolite (CNS7054) has approximately 300 times lower affinity for these receptors.
	Read more about Remimazolam

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
BYFAVO Powder for solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)
BYFAVO Powder for solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N05CD14		N Nervous system → N05 Psycholeptics → N05C Hypnotics and sedatives → N05CD Benzodiazepine derivatives
Discover more medicines within N05CD14

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1846076
FI	Lääkealan turvallisuus- ja kehittämiskeskus	426511
GB	Medicines & Healthcare Products Regulatory Agency	398859
LT	Valstybinė vaistų kontrolės tarnyba	1092326
PL	Rejestru Produktów Leczniczych	100461017
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W69478001
US	FDA, National Drug Code	71390-011